2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 355 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 355 | 355 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 355 | 355 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 20.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·16.4.I'm following along here.
·17.4.ja, I see it, affo, we'll just let it sit still, then hopefully something will happen eventually... good weekend then:-)- ·7.4. · MuokattuFor those who don't follow Sprint directly, I'm just passing on this post that VO2_Max posted today: Sprint Bioscience will present new preclinical data for its DCPS program at the AACR meeting in San Diego on April 17, 2026. The program has previously received a lot of attention. Sprint's CEO wrote a little over a year ago that about half of the meetings at BIO-Europe Spring were about DCPS, and that the interest also spilled over to their other projects. Sprint has had close dialogue with potential licensing partners about which preclinical research should be prioritized. The new data is therefore likely something that has been requested. CSO at Sprint has said that the new findings strengthen the program's clinical potential and that the project may now be approaching a first clinical study. The company plans to continue discussions with international pharmaceutical companies. In January, Amgen acquired Dark Blue for 840 million dollars, a company that also researches AML, which DCPS targets. Amgen stated that AML remains a difficult form of cancer to treat and that new mechanisms are necessary. Sprint sold the TREX1 cancer program to Gilead Sciences in November 2025 for an upfront amount of 14 million USD with potentially up to 400 million USD in milestones. Thanks to this agreement and the associated cash flow, Sprint had a cash position of around 127 million SEK at the beginning of 2026, which the company itself describes as a strengthened financial platform. The company has communicated that this cash balance, combined with continued cost discipline, provides solid coverage for operations and project activity into 2027 without immediate need for new capital. Do your own DD! This post was written on placera and rewritten into Norwegian via a spelling program·28.4.something about j.p. morgan and that teneo possibly will become the preferred one in their AI initiative or similar, but I am no data expert benielsen, so you MUST judge for yourself, have a nice day:-)
- ·1.4.Sprint Bioscience rises and rises and accounts for more and more in First Venture, without the share price of First Venture moving. One only pays for the cash holdings and the listed shares. The 65 % of the share, which consists of unlisted shares, one gets completely for free. See ibindex.se·16.4.it was read a long time ago, just wondered if you were still positive about this one? thanks for your great posts, wish you a continued good day:-)
- ·26.3.The discount is still insanely high. One already gets the entire large pool of unlisted shares completely free. Unfortunately, Rune Norlander is no longer part of the management, and one can therefore no longer follow his and Första Entrepenörfonden's acquisitions in the stock, as one could previously. But I'm guessing that he and the fund continue to buy up regularly and are major shareholders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16.4.I'm following along here.·17.4.ja, I see it, affo, we'll just let it sit still, then hopefully something will happen eventually... good weekend then:-)
- ·7.4. · MuokattuFor those who don't follow Sprint directly, I'm just passing on this post that VO2_Max posted today: Sprint Bioscience will present new preclinical data for its DCPS program at the AACR meeting in San Diego on April 17, 2026. The program has previously received a lot of attention. Sprint's CEO wrote a little over a year ago that about half of the meetings at BIO-Europe Spring were about DCPS, and that the interest also spilled over to their other projects. Sprint has had close dialogue with potential licensing partners about which preclinical research should be prioritized. The new data is therefore likely something that has been requested. CSO at Sprint has said that the new findings strengthen the program's clinical potential and that the project may now be approaching a first clinical study. The company plans to continue discussions with international pharmaceutical companies. In January, Amgen acquired Dark Blue for 840 million dollars, a company that also researches AML, which DCPS targets. Amgen stated that AML remains a difficult form of cancer to treat and that new mechanisms are necessary. Sprint sold the TREX1 cancer program to Gilead Sciences in November 2025 for an upfront amount of 14 million USD with potentially up to 400 million USD in milestones. Thanks to this agreement and the associated cash flow, Sprint had a cash position of around 127 million SEK at the beginning of 2026, which the company itself describes as a strengthened financial platform. The company has communicated that this cash balance, combined with continued cost discipline, provides solid coverage for operations and project activity into 2027 without immediate need for new capital. Do your own DD! This post was written on placera and rewritten into Norwegian via a spelling program·28.4.something about j.p. morgan and that teneo possibly will become the preferred one in their AI initiative or similar, but I am no data expert benielsen, so you MUST judge for yourself, have a nice day:-)
- ·1.4.Sprint Bioscience rises and rises and accounts for more and more in First Venture, without the share price of First Venture moving. One only pays for the cash holdings and the listed shares. The 65 % of the share, which consists of unlisted shares, one gets completely for free. See ibindex.se·16.4.it was read a long time ago, just wondered if you were still positive about this one? thanks for your great posts, wish you a continued good day:-)
- ·26.3.The discount is still insanely high. One already gets the entire large pool of unlisted shares completely free. Unfortunately, Rune Norlander is no longer part of the management, and one can therefore no longer follow his and Första Entrepenörfonden's acquisitions in the stock, as one could previously. But I'm guessing that he and the fund continue to buy up regularly and are major shareholders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 355 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 355 | 355 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 355 | 355 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 20.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 4.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 20.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16.4.I'm following along here.·17.4.ja, I see it, affo, we'll just let it sit still, then hopefully something will happen eventually... good weekend then:-)
- ·7.4. · MuokattuFor those who don't follow Sprint directly, I'm just passing on this post that VO2_Max posted today: Sprint Bioscience will present new preclinical data for its DCPS program at the AACR meeting in San Diego on April 17, 2026. The program has previously received a lot of attention. Sprint's CEO wrote a little over a year ago that about half of the meetings at BIO-Europe Spring were about DCPS, and that the interest also spilled over to their other projects. Sprint has had close dialogue with potential licensing partners about which preclinical research should be prioritized. The new data is therefore likely something that has been requested. CSO at Sprint has said that the new findings strengthen the program's clinical potential and that the project may now be approaching a first clinical study. The company plans to continue discussions with international pharmaceutical companies. In January, Amgen acquired Dark Blue for 840 million dollars, a company that also researches AML, which DCPS targets. Amgen stated that AML remains a difficult form of cancer to treat and that new mechanisms are necessary. Sprint sold the TREX1 cancer program to Gilead Sciences in November 2025 for an upfront amount of 14 million USD with potentially up to 400 million USD in milestones. Thanks to this agreement and the associated cash flow, Sprint had a cash position of around 127 million SEK at the beginning of 2026, which the company itself describes as a strengthened financial platform. The company has communicated that this cash balance, combined with continued cost discipline, provides solid coverage for operations and project activity into 2027 without immediate need for new capital. Do your own DD! This post was written on placera and rewritten into Norwegian via a spelling program·28.4.something about j.p. morgan and that teneo possibly will become the preferred one in their AI initiative or similar, but I am no data expert benielsen, so you MUST judge for yourself, have a nice day:-)
- ·1.4.Sprint Bioscience rises and rises and accounts for more and more in First Venture, without the share price of First Venture moving. One only pays for the cash holdings and the listed shares. The 65 % of the share, which consists of unlisted shares, one gets completely for free. See ibindex.se·16.4.it was read a long time ago, just wondered if you were still positive about this one? thanks for your great posts, wish you a continued good day:-)
- ·26.3.The discount is still insanely high. One already gets the entire large pool of unlisted shares completely free. Unfortunately, Rune Norlander is no longer part of the management, and one can therefore no longer follow his and Första Entrepenörfonden's acquisitions in the stock, as one could previously. But I'm guessing that he and the fund continue to buy up regularly and are major shareholders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 355 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 355 | 355 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 355 | 355 | 0 | 0 |